8 completed, 1 recruiting. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Recruiting 1 |
| Phase 1 | 4 | Completed 4 |
Follow Lytix Biopharma AS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma LTX-315 + pembrolizumab - Melanoma Stage IIIB-IV | Phase 2 | Recruiting | Oslo University Hospital | 27 | 2024-11-01 | 2024-10-26 |
| Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma LTX-315 in combination with pembrolizumab - Advanced Melanoma | Phase 2 | Completed | Lytix Biopharma AS | 23 | 2021-11-05 | 2026-09-10 |
| LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) LTX-315 and TILs - Soft Tissue Sarcoma | Phase 2 | Completed | Lytix Biopharma AS | 6 | 2018-12-28 | 2025-12-05 |
| LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab LTX-315 consecutive lesions, LTX-315, LTX-315 + ipilimumab - Cancer, Melanoma | Phase 1 | Completed | Lytix Biopharma AS | 80 | 2013-11-01 | 2018-10-03 |
| A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo LTX-109 1 %, LTX-109 2 %, Placebo gel - Non-bullous Impetigo | Phase 2 | Completed | Lytix Biopharma AS | 210 | 2013-02-01 | 2014-04-28 |
| A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection LTX-109 - Gram-positive, Skin Infections, Mild Eczema/Dermatoses | Phase 2 | Completed | Lytix Biopharma AS | 24 | 2010-09-01 | 2011-02-16 |
| A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma LTX-315 - Carcinoma | Phase 1 | Completed | Lytix Biopharma AS | 12 | 2010-08-01 | 2012-01-11 |
| A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA) LTX-109 - Nasal Carriers MRSA | Phase 1 / Phase 2 | Completed | Lytix Biopharma AS | 24 | 2010-05-01 | 2011-06-08 |
| Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour LTX-315 (Oncopore™) - Cancer With Transdermal Accessible Tumour | Phase 1 | Completed | Lytix Biopharma AS | 14 | 2010-01-01 | 2013-02-11 |
Melanoma (3) · Impetigo (2) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Cellulitis (1) · Dermatitis, Atopic (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Sarcoma (1) · Skin Diseases (1) · Triple Negative Breast Neoplasms (1)
LTX-315 (6) · pembrolizumab (3) · L-arginyl-2,5,7-tris(1,1-dimethylethyl)-L-tryptophyl-N-(2-phenylethyl)-L-argininamide (2) · GV1001 peptide (1) · Ipilimumab (1)
Norway (5) · France (2) · Sweden (2) · Belgium (1) · Denmark (1) · Dominican Republic (1) · Hungary (1) · Italy (1) · Spain (1) · United Kingdom (1) · United States (1)
Anna Nilsson, MD, PhD (1) · Daisy M Blanco, MD (1) · Inge Marie Svane, MD (1) · James Spicer, MD, PhD (1) · Josefina Fernandez, MD (1) · Lajos Kemeny, DSc, Prof (1) · Oystein Rekdal, PHD (1) · Paal Brunsvig, MD, PhD (1)
PMID 25331699, PMID 31177991, PMID 33542073, PMID 38125722
2023 (1)